A new immunotherapy target? How SRC-3 in Tregs may reshape solid-tumor treatment

MedicalXpress | مار 26, 2026

In 2023, researchers at Baylor College of Medicine led by the late Dr. Bert O'Malley discovered that the steroid receptor coactivator 3 (SRC-3) in immune cells called regulatory T cells (Tregs) plays a decisive role in shaping the anti-cancer immune response and that this could potentially be leveraged to develop more effective, long-lasting, side effect-free cancer treatments. The researchers didn't stop there, and they now have more promising results to report in a paper in OncoImmunology.